NCT04983810: An ongoing trial by Cyclacel Pharmaceuticals, Inc.
This trial is ongoing. It must report results 4 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04983810 |
|---|---|
| Title | A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 12, 2021 |
| Completion date | April 30, 2025 |
| Required reporting date | April 30, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |